Skip to main content

Table 1 Patient and biopsy characteristics

From: Three-dimensional greyscale transrectal ultrasound-guidance and biopsy core preembedding for detection of prostate cancer: Dutch clinical cohort study

 

Total

2D TRUS

3D TRUS

P value

Whole group (1339 patients)

Number of biopsy sessions

N = 1618

N = 1149 (71.0%)

N = 469 (29.0%)

 

Age in years, mean (SD)

63.4 (SD: 6.30)

63.0 (SD: 6.27)

64.6 (SD: 6.24)

< 0.001

PSA in ng/mL, mean (SD)

6.92 (SD: 1.84)

6.95 (SD: 1.85)

6.84 (SD: 1.84)

0.248

DRE:

 • benign, n (%)

1028 (68.3%)

739 (69.3%)

289 (65.7%)

0.167

 • suspicious, n (%)

478 (31.7%)

327 (30.7%)

151 (34.3%)

 

Prostate volume in ml, median (IQR)

41 (30–56)

40 (30–54)

46 (33–63)

< 0.001

Type of biopsy sessions:

 • Biopsy naive, n (%)

1238 (76.5%)

863 (75.1%)

375 (80.0%)

0.037

 • Prior negative, n (%)

380 (23.5%)

286 (24.9%)

94 (20.0%)

 

Type of operator:

 • Experienced, n (%)

843 (52.1%)

498 (43.3%)

345 (73.6%)

<  0.001

 • Less experienced, n (%)

775 (47.9%)

651 (56.7%)

124 (26.4%)

 

Biopsy cores per session, mean (SD)

12.3 (SD 1.04)

12.3 (SD 1.05)

12.3 (SD 1.02)

0.555

Biopsy sessions with fragmentation, n (%)

442 (27.3%)

433 (37.7%)

9 (1.9%)

< 0.001

Length of biopsy cores in mm, mean (SD)a

13.84 (SD: 2.98)

12.38 (SD: 2.82)

16.08 (SD: 1.41)

< 0.001

Biopsy naïve group (1238 patients)

Number of biopsy sessions

N = 1238

N = 863 (69.7%)

N = 375 (30.3%)

 

Age in years, mean (SD)

63.5 (SD: 6.46)

63.0 (SD: 6.43)

64.7 (SD: 6.35)

< 0.001

PSA in ng/mL, mean (SD)

6.73 (SD: 1.87)

6.72 (SD: 1.87)

6.74 (SD: 1.86)

0.877

DRE:

 • benign, n (%)

777 (66.9%)

556 (68.6%)

221 (63.0%)

0.063

 • suspicious, n (%)

385 (33.1%)

255 (31.4%)

130 (37.0%)

 

Prostate volume in ml, median (IQR)

40 (30–55)

40 (29–52)

44 (32–60)

< 0.001

Type of operator:

• Experienced, n (%)

643 (51.9%)

368 (42.6%)

275 (73.3%)

< 0.001

• Less experienced, n (%)

595 (48.1%)

495 (57.4%)

100 (26.7%)

 

Biopsy cores per session, mean (SD)

12.2 (SD 0.79)

12.2 (SD 0.80)

12.2 (SD 0.77)

0.779

Biopsy sessions with fragmentation, n (%)

334 (27.0%)

325 (37.7%)

9 (2.4%)

< 0.001

Length of biopsy cores in mm, mean (SD)a

13.84 (SD: 2.96)

12.33 (SD: 2.78)

16.07 (SD: 1.40)

< 0.001

Prior negative group (321 patients)

Number of biopsy sessions

N = 380

N = 286 (75.3%)

N = 94 (24.7%)

 

Prior negative sessions specified:

 • Second session

300 (78.9%)

225 (78.7%)

75 (79.8%)

0.658

 • Third session

64 (16.8%)

47 (16.4%)

17 (18.1%)

 

 • Fourth session

14 (3.7%)

12 (4.2%)

2 (2.1%)

 

 • Fifth session

2 (0.5%)

2 (0.7%)

0

 

Age in years, mean (SD)

63.1 (SD: 5.79)

62.8 (SD: 5.80)

63.9 (SD: 5.73)

0.135

PSA in ng/mL, mean (SD)

7.54 (SD: 1.60)

7.65 (SD: 1.54)

7.20 (SD: 1.73)

0.023

DRE:

 • benign, n (%)

251 (73.0%)

183 (71.8%)

68 (76.4%)

0.396

 • suspicious, n (%)

93 (27.0%)

72 (28.2%)

21 (23.6%)

 

Prostate volume in ml, median (IQR)

46 (32–62)

44 (31–58)

54 (39–70)

< 0.001

Type of operator:

 • Experienced, n (%)

200 (52.6%)

130 (45.5%)

70 (74.5%)

< 0.001

 • Less experienced, n (%)

180 (47.4%)

156 (54.5%)

24 (25.5%)

 

Biopsy cores per session, mean (SD)

12.6 (SD 1.56)

12.7 (SD 1.53)

12.6 (SD 1.67)

0.519

Biopsy sessions with fragmentation, n (%)

113 (29.7%)

113 (39.2%)

0

< 0.001

Length of biopsy cores in mm, mean (SD)a

13.81 (SD: 3.05)

12.54 (SD: 2.96)

16.10 (SD: 1.48)

< 0.001

  1. aBiopsy sessions with fragmentation were excluded for these analyses